Efficacy of breast cancer screening in the community according to risk level.

BACKGROUND The efficacy of breast cancer screening in the community may differ from that suggested by the results of randomized trials, and no data have been available on efficacy among women who have different levels of breast cancer risk. METHODS We conducted a matched case-control study among women enrolled in six health plans in Washington, Oregon, California, Massachusetts, and Minnesota. We examined the efficacy of screening by mammography and/or clinical breast examination among women in two age cohorts (40-49 years and 50-65 years) and in two breast cancer risk levels (average and increased risk). Women who died from breast cancer from January 1, 1983, through December 31, 1998, (N = 1351; case subjects) were matched to control subjects (N = 2501) on age and risk level. Increased risk was defined as a family history of breast cancer or a breast biopsy noted in the medical records before the index date (defined as date of first suspicion of breast abnormalities in case subjects, with the same date used for matched control subjects). Data on screening, risk status, and other variables were abstracted from medical records. Conditional logistic regression was used to examine the association between breast cancer mortality and receipt of screening. All statistical tests were two-sided. RESULTS There were small, non-statistically significant associations between breast cancer mortality and receipt of screening during the 3 years prior to the index date for both the younger women [odds ratio (OR) = 0.92; 95% confidence interval (CI) = 0.76 to 1.13] and the older women (OR = 0.87; 95% CI = 0.68 to 1.12). The association among women at increased risk (OR = 0.74; 95% CI = 0.50 to 1.03) was stronger than that among women at average risk (OR = 0.96; 95% CI = 0.80 to 1.14), but the difference was not statistically significant (P = .17). CONCLUSIONS In this community-based study, screening history was not associated with breast cancer mortality. However, potential limitations of this study argue for a cautious interpretation of these findings.

[1]  Russell P. Harris.  Effectiveness: the next question for breast cancer screening. , 2005, Journal of the National Cancer Institute.

[2]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[3]  D. Petitti,et al.  Saving Women's Lives: Strategies for Improving Breast Cancer Detection and Diagnosis , 2005 .

[4]  A. Miller.  Commentary: a defence of the Health Insurance Plan (HIP) study and the Canadian National Breast Screening Study (CNBSS). , 2004, International journal of epidemiology.

[5]  Emily White,et al.  Predictors of Sensitivity of Clinical Breast Examination (CBE) , 2002, Breast Cancer Research and Treatment.

[6]  Karla Kerlikowske,et al.  Comparison of screening mammography in the United States and the United kingdom. , 2003, JAMA.

[7]  C. Baines.  Mammography screening: are women really giving informed consent? , 2003, Journal of the National Cancer Institute.

[8]  C. D'Orsi,et al.  International variation in screening mammography interpretations in community-based programs. , 2003, Journal of the National Cancer Institute.

[9]  L. Tabár,et al.  Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening , 2003, The Lancet.

[10]  Joann G. Elmore,et al.  Mammographic Screening for Breast Cancer , 2003 .

[11]  Sarah M. Greene,et al.  Training, quality assurance, and assessment of medical record abstraction in a multisite study. , 2003, American journal of epidemiology.

[12]  Joann G Elmore,et al.  Does practice make perfect when interpreting mammography? Part II. , 2003, Journal of the National Cancer Institute.

[13]  Emily F Conant,et al.  Association of volume and volume-independent factors with accuracy in screening mammogram interpretation. , 2003, Journal of the National Cancer Institute.

[14]  Joann G Elmore,et al.  Clinical practice. Mammographic screening for breast cancer. , 2003, The New England journal of medicine.

[15]  Ingvar Andersson,et al.  Long-term effects of mammography screening: updated overview of the Swedish randomised trials , 2002, The Lancet.

[16]  J. Elmore,et al.  Does practice make perfect when interpreting mammography? , 2002, Journal of the National Cancer Institute.

[17]  Helen C. Cowley,et al.  Improving the accuracy of mammography: volume and outcome relationships. , 2002, Journal of the National Cancer Institute.

[18]  D. Zuckerman,et al.  Screening for breast cancer with mammography , 2001, The Lancet.

[19]  Peter C Gøtzsche,et al.  Cochrane review on screening for breast cancer with mammography , 2001, The Lancet.

[20]  M Zelen,et al.  Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Miller,et al.  Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. , 2000, Journal of the National Cancer Institute.

[22]  A. Basiński.  Review: High-quality studies do not show reductions in breast cancer mortality for women screened with mammography , 2000, ACP Journal Club.

[23]  N. Lee,et al.  Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. , 2000, Journal of the National Cancer Institute.

[24]  Mike Clarke,et al.  UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.

[25]  P. Prorok,et al.  Investigation of design and bias issues in case-control studies of cancer screening using microsimulation. , 2000, American journal of epidemiology.

[26]  Stephen W Duffy,et al.  Screening mammography re-evaluated , 2000, The Lancet.

[27]  Peter C Gøtzsche,et al.  Is screening for breast cancer with mammography justifiable? , 2000, The Lancet.

[28]  Daniel S. Miller,et al.  Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)--Behavioral Risk Factor Surveillance System. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[29]  S. Fletcher,et al.  The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? , 1999, JAMA.

[30]  S. Moss.  A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40 , 1999, Journal of medical screening.

[31]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[32]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[33]  J. Elmore,et al.  Does diagnostic accuracy in mammography depend on radiologists' experience? , 1998, Journal of women's health.

[34]  J. Elmore,et al.  Ten-year risk of false positive screening mammograms and clinical breast examinations. , 1998, The New England journal of medicine.

[35]  K. Demissie,et al.  Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography. , 1998, Journal of clinical epidemiology.

[36]  W. Barlow,et al.  Breast cancer survival and treatment in health maintenance organization and fee-for-service settings. , 1997, Journal of the National Cancer Institute.

[37]  L. Tabár,et al.  Markov models of breast tumor progression: some age-specific results. , 1997, Journal of the National Cancer Institute. Monographs.

[38]  A. Threlfall,et al.  Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region , 1995, BMJ.

[39]  N. Weiss,et al.  Application of the case-control method in the evaluation of screening. , 1994, Epidemiologic reviews.

[40]  S Shapiro,et al.  Report of the International Workshop on Screening for Breast Cancer. , 1993, Journal of the National Cancer Institute.

[41]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[42]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[43]  W. Odling-Smee,et al.  Screening for Breast Cancer , 1985, The Lancet.

[44]  J H Lubin,et al.  Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.

[45]  S D Walter,et al.  Estimation of the duration of a pre-clinical disease state using screening data. , 1983, American journal of epidemiology.

[46]  N. Weiss.  Control definition in case-control studies of the efficacy of screening and diagnostic testing. , 1983, American journal of epidemiology.

[47]  Alan S. Marrison.  Case definition in case-control studies of the efficacy of screening. , 1982 .

[48]  K. Kupka,et al.  International classification of diseases: ninth revision. , 1978, WHO chronicle.